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cirrhosis, will continue to be encouraged by the international
hepatology community.
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Letters to the EditorTo the Editor:
The role of metabolic alterations and adaptations is becoming
increasingly evident in the pathogenesis of cirrhosis and hepato-
cellular carcinoma (HCC) [1–4]. Using a rat model of cirrhosis,
Nishikawa et al. [5] demonstrate that early stage cirrhotic hepa-
tocytes switch to glycolysis to meet their energy requirements
as a result of a decline in oxidative phosphorylation, but that this
mechanism fails in late cirrhosis. Since HCC typically arises in the
background of liver cirrhosis [6] and also encompasses a glyco-
lytic phenotype [7], it would be important to determine how this
is related to the altered metabolism of cirrhotic hepatocytes.
Since early cirrhotic cells are more glycolytic than advanced or
failing cirrhotic cells, it remains unclear as to whether the
progression of HCC is facilitated by metabolically active early
cirrhotic cells or represents an escape mechanism of late cirrhotic
hepatocytes which are unable to sustain their energy demands.
Conﬂict of interest
The authors declare that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.References
[1] Krahenbuhl S, Reichen J. Adaptation of mitochondrial metabolism in liver
cirrhosis. Different strategies tomaintain a vital function. Scand J Gastroenterol
Suppl 1992;193:90–96.
Esteban Mezey
Department of Medicine, The Johns Hopkins
University School of Medicine, Baltimore, MD, USA
452 Journal of Hepatology 2014 vol. 61 j 449–455
Open access under CC BY-NC-ND license.
